Article detail · 2018
The exogenous administration of CB2 specific agonist, GW405833, inhibits inflammation by reducing cytokine production and oxidative stress
Journal
Experimental and Therapeutic MedicineISSN 1792-0981
The ISSN points to another catalog journal; the name is from the YÖKSİS record.
- Year
- 2018
- Type
- article
Data source split
- YÖKSİS YÖKSİS article record
- YÖKSİS venue Experimental and Therapeutic Medicine
- Catalog match (ISSN) Experimental and Therapeutic Medicine (discontinued)
- OpenAlex OpenAlex enrichment (abstract, citations, topics)
Abstract
OpenAlex · English
The present study aimed to investigate the role of cannabinoid 2 (CB2) receptors in a rat model of acute inflammation. Therefore, the potential of anti-inflammatory effects of CB2 receptor agonist (GW405833), CB2 receptor antagonist (AM630), and diclofenac, were investigated in carrageenan induced paw oedema in rats: as were assessed by measuring paw oedema; myeloperoxidase (MPO) activity in paw tissue; malondialdehyde (MDA) concentration; glutathione (GSH) level in paw tissue for oxidant/antioxidant balance; cytokine (interleukin-1β, IL-1β; tumour necrosis factor-α, TNF-α) levels in serum; histopathology of paw tissue for inflammatory cell accumulations. The results showed that GW405833 or diclofenac significantly reduced carrageenan-induced paw oedema. GW405833 also inhibited the increase of MPO activity, the recruitment of total leukocytes and neutrophils, and MDA concentration during carrageenan-induced acute inflammation, along with reversed nearly to the normal levels the increased of TNF-α, and IL-1β in serum. AM630 did not affect inflammation alone however clearly reversed the effects of agonist when co-administered. The mechanism of GW405833's suppression of inflammation is supported by these results, which are achieved by the inhibition of neutrophil migration, which regulates the reduction of oxidative stress, TNF-α and IL-1β levels. Finally, the activation of CB2 receptor, by selective agonist, has a major role in peripheral inflammation, and in the near future, targeting the peripheral cannabinoid system as a promising alternative to treat inflammation diseases may be considered a novel pharmacologic approach.
Topics
Citations
OpenAlex cited_by_count. Not a WoS or Scopus citation count; those sources have no separate column here.
43 citations
OpenAlex cited_by_count (cache / database)
22 publications in the local catalog that cite this work (OpenAlex reference match; not the full global list).
- Glabridin alleviates inflammation and nociception in rodents by activating BKCa channels and reducing NO levels 2020
- Glabridin Alleviates Inflammation and Nociception in Rodents by Activating BKCa Channels and Reducing NO Levels 2020
- Effects of cannabinoid receptor 2 synthetic agonist, AM1241, on bleomycin induced pulmonary fibrosis 2021
- Effects of cannabinoid receptor 2 synthetic agonist, AM1241, on bleomycin induced pulmonary fibrosis 2021
- Effects of cannabinoid receptor 2 synthetic agonist, AM1241, on bleomycin induced pulmonary fibrosis 2021
- Effects of cannabinoid receptor 2 synthetic agonist, AM1241, on bleomycin induced pulmonary fibrosis 2021
- EFFECTS OF CANNABINOID RECEPTOR 2 SYNTHETIC AGONIST, AM1241, ON BLEOMYCIN INDUCED PULMONARY FIBROSIS 2021
- Effects of cannabinoid receptor 2 synthetic agonist, AM1241, on bleomycin induced pulmonary fibrosis 2020
- PRETREATMENT WITH GLABRIDIN PREVENTS CARRAGEENAN-INDUCED INFLAMMATION: THE ROLES FOR CYTOKINES AND OXIDATIVE STRESS PRODUCTION 2021
- PRETREATMENT WITH GLABRIDIN PREVENTS CARRAGEENAN-INDUCED INFLAMMATION: THE ROLES FOR CYTOKINES AND OXIDATIVE STRESS PRODUCTION 2021